# VIOLETTE (NCT03330847)

> To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03330847
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Metastatic Triple Negative Breast Cancer
- Interventions: Olaparib Continuous (28-Day cycle) 300 mg BD.; Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).; Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Enrollment: 273
- Primary outcome: Progression-free Survival Per Stratum (BICR)
- Primary outcome: Progression-free Survival Per Stratum (Sensitivity Analysis)

## Indexed commentary on VIOLETTE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=violette-nct03330847